The Latest Cardiac and Vascular News
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with […]
January 29, 2025 11:05 AM Eastern Standard Time SOUTHLAKE, Texas–(BUSINESS WIRE)–Rapid Medical™, a leading developer of active endovascular devices, announces the first patient enrolled in its COGNITIVE Study–the first to examine a link between mechanical thrombectomy and cognitive improvement. TIGERTRIEVER, the only active stent retriever, may uniquely preserve cognitive function with […]
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
WAYNE, Penn.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. “What we endeavor to understand In POINT FORCE is the role Serranation can […]
SAN FRANCISCO, Jan. 28, 2025 /PRNewswire/ — Sirona Medical, a leader in cloud-native radiology workflow solutions, announced the appointment of Ken Kaufman as Chief Executive Officer. Kaufman is a seasoned executive and business builder with a distinguished career spanning radiology and…
Niagara Falls, NY, Jan. 28, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices.
BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization…
PASADENA, Calif., Jan. 28, 2025 /PRNewswire/ — Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, provides crucial insights into predicting the long-term risk for cardiovascular damage from e-cigarettes…
LEIDEN, The Netherlands–(BUSINESS WIRE)–Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery. “With Ncyte® Heart in a Box, we are empowering researchers to […]
